Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1955 2
1964 1
1966 2
1967 2
1968 1
1969 1
1970 1
1971 1
1975 2
1979 1
2010 4
2013 1
2014 4
2016 1
2017 3
2018 1
2021 1
2022 3
2023 8
2024 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45 results

Results by year

Filters applied: . Clear all
Page 1
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
Howard JF Jr, Bril V, Vu T, Karam C, Peric S, Margania T, Murai H, Bilinska M, Shakarishvili R, Smilowski M, Guglietta A, Ulrichts P, Vangeneugden T, Utsugisawa K, Verschuuren J, Mantegazza R; ADAPT Investigator Study Group. Howard JF Jr, et al. Lancet Neurol. 2021 Jul;20(7):526-536. doi: 10.1016/S1474-4422(21)00159-9. Lancet Neurol. 2021. PMID: 34146511 Clinical Trial.
Cognitive disorders in patients with chronic kidney disease: Approaches to prevention and treatment.
Pépin M, Klimkowicz-Mrowiec A, Godefroy O, Delgado P, Carriazo S, Ferreira AC, Golenia A, Malyszko J, Grodzicki T, Giannakou K, Paolisso G, Barbieri M, Garneata L, Mocanu CA, Liabeuf S, Spasovski G, Zoccali C, Bruchfeld A, Farinha A, Arici M, Capasso G, Wiecek A, Massy ZA; CONNECT (Cognitive Decline in Nephro-Neurology: European Cooperative Target) Action. Pépin M, et al. Among authors: golenia a. Eur J Neurol. 2023 Sep;30(9):2899-2911. doi: 10.1111/ene.15928. Epub 2023 Jun 29. Eur J Neurol. 2023. PMID: 37326125 Free article. Review.
Drugs with a negative impact on cognitive functions (Part 2): drug classes to consider while prescribing in CKD patients.
Hafez G, Malyszko J, Golenia A, Klimkowicz-Mrowiec A, Ferreira AC, Arıcı M, Bruchfeld A, Nitsch D, Massy ZA, Pépin M, Capasso G, Mani LY, Liabeuf S; CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative Target). Hafez G, et al. Among authors: golenia a. Clin Kidney J. 2023 Sep 18;16(12):2378-2392. doi: 10.1093/ckj/sfad239. eCollection 2023 Dec. Clin Kidney J. 2023. PMID: 38046029 Free PMC article. Review.
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, Campbell SE, Oshima R, Amarenco P, Blom DJ, Brinton EA, Eckel RH, Elam MB, Felicio JS, Ginsberg HN, Goudev A, Ishibashi S, Joseph J, Kodama T, Koenig W, Leiter LA, Lorenzatti AJ, Mankovsky B, Marx N, Nordestgaard BG, Páll D, Ray KK, Santos RD, Soran H, Susekov A, Tendera M, Yokote K, Paynter NP, Buring JE, Libby P, Ridker PM; PROMINENT Investigators. Das Pradhan A, et al. N Engl J Med. 2022 Nov 24;387(21):1923-1934. doi: 10.1056/NEJMoa2210645. Epub 2022 Nov 5. N Engl J Med. 2022. PMID: 36342113 Clinical Trial.
Drugs with a negative impact on cognitive function (Part 1): chronic kidney disease as a risk factor.
Liabeuf S, Pešić V, Spasovski G, Maciulaitis R, Bobot M, Farinha A, Wagner CA, Unwin RJ, Capasso G, Bumblyte IA, Hafez G; CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative Target). Liabeuf S, et al. Clin Kidney J. 2023 Sep 18;16(12):2365-2377. doi: 10.1093/ckj/sfad241. eCollection 2023 Dec. Clin Kidney J. 2023. PMID: 38045996 Free PMC article. Review.
Drugs with a negative impact on cognitive functions (part 3): antibacterial agents in patients with chronic kidney disease.
Liabeuf S, Hafez G, Pešić V, Spasovski G, Bobot M, Mačiulaitis R, Bumblyte IA, Ferreira AC, Farinha A, Malyszko J, Pépin M, Massy ZA, Unwin R, Capasso G, Mani LY; CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative Target). Liabeuf S, et al. Clin Kidney J. 2024 Jun 14;17(8):sfae174. doi: 10.1093/ckj/sfae174. eCollection 2024 Aug. Clin Kidney J. 2024. PMID: 39114495 Free PMC article. Review.
Methodological challenges and biases in the field of cognitive function among patients with chronic kidney disease.
Giannakou K, Golenia A, Liabeuf S, Malyszko J, Mattace-Raso F, Farinha A, Spasovski G, Hafez G, Wiecek A, Capolongo G, Capasso G, Massy ZA, Pépin M. Giannakou K, et al. Among authors: golenia a. Front Med (Lausanne). 2023 Aug 9;10:1215583. doi: 10.3389/fmed.2023.1215583. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37621458 Free PMC article. Review.
Translational research on cognitive impairment in chronic kidney disease.
Wagner CA, Massy ZA, Capasso G, Mattace-Raso F, Pepin M, Bobot M, Zoccali C, Ferreira AC, Hoorn EJ, Silva PHI, Unwin RJ, Pesic V; CONNECT. Wagner CA, et al. Nephrol Dial Transplant. 2024 Oct 14:gfae229. doi: 10.1093/ndt/gfae229. Online ahead of print. Nephrol Dial Transplant. 2024. PMID: 39400744
Factor XIII.
Adamski MG, Turaj W, Wnuk M, Golenia A, Krupa M, Moskala M, Szczudlik A, Słowik A. Adamski MG, et al. Among authors: golenia a. J Neurosurg. 2010 Aug;113(2):400-1. doi: 10.3171/2009.11.JNS091705. J Neurosurg. 2010. PMID: 20578803 No abstract available.
45 results